

\*\*\*\*Published October 2023\*\*\*\*

## MarketVIEW: *Group B Streptococcus* vaccines (CAT: VAMV008)

<b>Product Name</b>	:	<b>MarketVIEW: <i>Group B Streptococcus</i> vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (>300 slides.pdf) + forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>New bacterial vaccines</b>
<b>Publication date</b>	:	October 2023
<b>Catalogue No</b>	:	VAMV008

### Background

**Group B Streptococcus** or *Streptococcus agalactiae* is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all ages. In the neonate, the bacterium can cause severe life threatening sepsis, meningitis and pneumonia (early-onset, EOGBS and late-onset LOGBS disease) due to ascending spread of GBS from the birth canal of colonized females (~18-30% colonized of total) who are typically asymptomatic. GBS may also contribute to stillbirth, pre-mature birth, neonatal encephalopathy and long-term neurological outcomes in meningitis survivors. It can cause perinatal clinical syndromes in the mother during such as maternal sepsis and chorioamnionitis. Globally, GBS was estimated to have caused 394,000 cases of invasive neonatal disease resulting in 91,900 deaths (95% CI 44,800-187,800) (Goncalves BP *et al* 2022).

A prophylactic **Group B Streptococcus vaccine** could prevent invasive disease in a number of target populations both in Western developed countries and the developing world e.g., GAVI-assisted countries. Several approaches are ongoing in both preclinical and clinical development with the most advanced being the **Pfizer, GBS6 vaccine [PF-06760805]**, a hexavalent polysaccharide conjugated approach which recently reported positive data from an ongoing Phase 2 study. Danish-based **Minervax** are also developing an adjuvanted protein-based GBS vaccine (GBS-NN, GBS-NN2) for maternal (Phase 2) and adult indications (Phase 1). Other earlier potential approaches are being pursued by Nanjing Agricultural University, China and the US-biotech, **Omniose**.

This **MarketVIEW** product is a comprehensive Executive Presentation (>300 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls) which investigate the scenario-based uptake and commercial potential of Group B Streptococcus vaccines across key target groups in 118 nations (public/private) worldwide including HI income and GAVI/developing world countries. A thorough review of latest disease background/epidemiology/resistance trends data is presented along with discussion of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth scenario-based commercial assessment of potential GBS vaccine profiles with discussion around target population rationale, potential uptake, pricing, cost-effectiveness and clinical development feasibility/issues.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to *Group B Streptococcus* epidemiology (healthcare-associated infections/neonatal sepsis) and resistance trends in each respective market/globally. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of bacterial pathogens has also been utilised.

### PRODUCT CONTENTS:

Published October 2023 (CAT No: VAMV008)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

#### Contents – Summary presentation (.pdf)



Contents

Author's notes

#### Executive summary

**[SECTION 1]** *Group B Streptococcus* vaccines: commercial model – key outputs

**[SECTION 2]** *Group B Streptococcus*: the pathogen, disease background, pathogenesis

**[SECTION 3]** *Group B Streptococcus*: review of molecular epidemiology

**[SECTION 4]** *Group B Streptococcus*: review of disease burden and impact

**[SECTION 5]** *Group B Streptococcus* vaccines: review of current screening policies, IAP

**[SECTION 6]** *Group B Streptococcus* vaccines: vaccine development, current R&D, considerations

**[SECTION 7]** *Group B Streptococcus* vaccines: Rationale, WHO TPP/FVA, Cost-effectiveness

**[SECTION 8]** *Group B Streptococcus* vaccines: modelling commercial potential [Western/GAVI]

References/bibliography

About **VacZine Analytics**

Disclaimer

**SNAPSHOT**

**PAGES: >300 slides fully referenced/sourced. Available in .pdf form**

#### Contents – MS-Excel workbook (.xls)



3 uptake scenarios: LO/BASE and HI

118 countries (5 groups) included in 2 x global demand model(s)

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$12,995.00**/ GBP **£10,995.00**# (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

# - *indicative prevailing rate will be applied on date of transaction*

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




**VacZine Analytics** ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** ® and the “spiral logo” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

References – available upon request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd  
Warren (Carlton) House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 927049  
E-mail: [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)



## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and "the spiral logo" are UK Registered Trademarks, 2009



*Since 2007*

